Skip to content 
Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of engineered antibodies for the treatment of cancer and autoimmune diseases. The company provides Ultomiris to treat patients with atypical hemolytic uremic syndrome, generalized myasthenia gravis, and neuromyelitis optica spectrum disororder; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It also develops XmAb819, a bispecific antibody to treat renal cell carcinoma; XmAb541, which is in Phase I for the treatment of ovarian cancer; XmAb808, a bispecific antibody that binds to the broadly expressed tumor antigen; XmAb942, which is in clinical development for patients with Crohn's disease and ulcerative colitis; Plamotamab, a bispecific T-cell, which is in Phase Ib study to treat rheumatoid arthritis; and XmAb657 for patients with idiopathic inflammatory myopathies. Further, the company develops Xaluritamig, a bispecific T-cell engager that treats prostate cancer; ASP2138 to treat gastric, gastroesophageal junction, and pancreatic cancers; JNJ-9401 to treat metastatic castration-resistant prostate cancer; Obexelimab, an antibody to treat patients with autoimmune diseases; Tobevibart, a treatment for chronic hepatitis Delta; Zaltenibart to treat paroxysmal nocturnal hemoglobinuria and other alternative pathway disorders; Teropavimab and zinlirvimab to treat human immunodeficiency virus; Novartis, an antibody drug candidate that uses XmAb Fc technologies; and JNJ-1493 to treat B-cell malignancies. The company was incorporated in 1997 and is headquartered in Pasadena, California. more
| Time Frame | XNCR | Sector | S&P500 |
|---|---|---|---|
| 1-Week Return | -11.35% | -3.93% | -0.67% |
| 1-Month Return | -2.5% | -2.41% | -1.33% |
| 3-Month Return | -35.97% | 1.64% | -0.29% |
| 6-Month Return | 34.6% | 11.65% | 5.08% |
| 1-Year Return | -18.27% | 3.11% | 19.01% |
| 3-Year Return | -64.5% | 19.21% | 68.62% |
| 5-Year Return | -73.67% | 36.52% | 78.6% |
| 10-Year Return | -5.67% | 126.5% | 240.69% |
| Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | 5YR TREND | |
|---|---|---|---|---|---|---|
| Total Revenue | 275.11M | 164.58M | 168.34M | 110.49M | 125.58M | [{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":59.82,"profit":true},{"date":"2023-12-31","value":61.19,"profit":true},{"date":"2024-12-31","value":40.16,"profit":true},{"date":"2025-12-31","value":45.65,"profit":true}] |
| Cost of Revenue | 7.49M | 8.80M | 253.60M | 12.11M | 10.51M | [{"date":"2021-12-31","value":2.95,"profit":true},{"date":"2022-12-31","value":3.47,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":4.77,"profit":true},{"date":"2025-12-31","value":4.15,"profit":true}] |
| Gross Profit | 275.11M | 164.58M | (85.26M) | 110.49M | 115.06M | [{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":59.82,"profit":true},{"date":"2023-12-31","value":-30.99,"profit":false},{"date":"2024-12-31","value":40.16,"profit":true},{"date":"2025-12-31","value":41.82,"profit":true}] |
| Gross Margin | 100.00% | 100.00% | (50.65%) | 100.00% | 91.63% | [{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-50.65,"profit":false},{"date":"2024-12-31","value":100,"profit":true},{"date":"2025-12-31","value":91.63,"profit":true}] |
| Operating Expenses | 231.34M | 247.05M | 306.98M | 288.90M | 292.57M | [{"date":"2021-12-31","value":75.36,"profit":true},{"date":"2022-12-31","value":80.48,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":94.11,"profit":true},{"date":"2025-12-31","value":95.31,"profit":true}] |
| Operating Income | 43.77M | (82.47M) | (138.64M) | (178.41M) | (177.50M) | [{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-188.44,"profit":false},{"date":"2023-12-31","value":-316.77,"profit":false},{"date":"2024-12-31","value":-407.63,"profit":false},{"date":"2025-12-31","value":-405.56,"profit":false}] |
| Total Non-Operating Income/Expense | 39.71M | 32.78M | 31.94M | (61.23M) | - | [{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":82.55,"profit":true},{"date":"2023-12-31","value":80.43,"profit":true},{"date":"2024-12-31","value":-154.18,"profit":false},{"date":"2025-12-31","value":"-","profit":true}] |
| Pre-Tax Income | 82.63M | (54.51M) | (120.44M) | (234.92M) | (89.42M) | [{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-65.97,"profit":false},{"date":"2023-12-31","value":-145.76,"profit":false},{"date":"2024-12-31","value":-284.3,"profit":false},{"date":"2025-12-31","value":-108.21,"profit":false}] |
| Income Taxes | (7.49M) | 673.00K | 5.81M | 1.62M | 2.50M | [{"date":"2021-12-31","value":-128.91,"profit":false},{"date":"2022-12-31","value":11.58,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":27.83,"profit":true},{"date":"2025-12-31","value":43.09,"profit":true}] |
| Income After Taxes | 90.12M | (55.18M) | (126.25M) | (236.54M) | - | [{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-61.23,"profit":false},{"date":"2023-12-31","value":-140.09,"profit":false},{"date":"2024-12-31","value":-262.47,"profit":false},{"date":"2025-12-31","value":"-","profit":true}] |
| Income From Continuous Operations | 82.63M | (55.18M) | (119.03M) | (236.54M) | - | [{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-66.78,"profit":false},{"date":"2023-12-31","value":-144.05,"profit":false},{"date":"2024-12-31","value":-286.26,"profit":false},{"date":"2025-12-31","value":"-","profit":true}] |
| Income From Discontinued Operations | - | - | - | - | - | [{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true},{"date":"2025-12-31","value":"-","profit":true}] |
| Net Income | 82.63M | (55.18M) | (126.09M) | (232.62M) | (91.92M) | [{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-66.78,"profit":false},{"date":"2023-12-31","value":-152.59,"profit":false},{"date":"2024-12-31","value":-281.51,"profit":false},{"date":"2025-12-31","value":-111.25,"profit":false}] |
| EPS (Diluted) | 1.35 | (0.93) | (2.10) | (3.51) | (1.24) | [{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-68.89,"profit":false},{"date":"2023-12-31","value":-155.56,"profit":false},{"date":"2024-12-31","value":-260,"profit":false},{"date":"2025-12-31","value":-91.85,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
| XNCR | |
|---|---|
| Cash Ratio | 4.54 |
| Current Ratio | 6.25 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
| XNCR | |
|---|---|
| ROA (LTM) | -12.14% |
| ROE (LTM) | -14.07% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
| XNCR | |
|---|---|
| Debt Ratio Lower is generally better. Negative is bad. | 0.27 |
| Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.73 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
| XNCR | |
|---|---|
| Trailing PE | NM |
| Forward PE | NM |
| P/S (TTM) | 6.52 |
| P/B | 1.45 |
| Price/FCF | NM |
| EV/R | 3.38 |
| EV/Ebitda | NM |
| PEG | NM |
Xencor Inc (XNCR) share price today is $11.32
Yes, Indians can buy shares of Xencor Inc (XNCR) on Vested. To buy
Yes, you can purchase fractional shares of Xencor Inc (XNCR) via the Vested app. You can start investing in Xencor Inc (XNCR) with a minimum investment of $1.
You can invest in shares of Xencor Inc (XNCR) via Vested in three simple steps:
The 52-week high price of Xencor Inc (XNCR) is $18.69. The 52-week low price of Xencor Inc (XNCR) is $6.92.
The price-to-earnings (P/E) ratio of Xencor Inc (XNCR) is
The price-to-book (P/B) ratio of Xencor Inc (XNCR) is 1.45
The dividend yield of Xencor Inc (XNCR) is 0.00%
The market capitalization of Xencor Inc (XNCR) is $818.46M
The stock symbol (or ticker) of Xencor Inc is XNCR
Consider the share price of Xencor Inc as a long-term story and not a daily point list. The price represents a movement of the stock in both good and bad times when looked at over many years. This assists the investors to know whether Xencor Inc has succeeded to expand steadily and overcome market declines. With this price movement observed and the way the business is progressing, it is easier to make a decision whether the stock is worth having in the long term or not.
When investing in Xencor Inc shares, you are not based in India then your investment is not just based on the stock price. It is also determined by the currency movement of the dollar in relation to the rupee. When you have an appreciation of the Xencor Inc stock and the dollar appreciation is also the same, you gain more in terms of rupees. When the rupee appreciated, it will lower your profits. This currency flow is a silent cause of great contribution to your ultimate returns over many years.
Rather than merely checking the share price of Xencor Inc and comparing it with that of other stocks in the same sector, one can check how robust the business is. Investors tend to compare such aspects as profits, cash generation, and the stability of the revenues of the company. This means that Xencor Inc stock in most cases does not react in the same manner as other companies in the sector due to its brand and services revenue.
Link copied 
